Clario Announces Sale of Software Solutions Business to Sitero
PHILADELPHIA, PA – August 1, 2023 – Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced the sale of its Software Solutions business, an end-to-end solution to support the clinical trial lifecycle.
The Clario eClinical product suite (including CTMS, eConsent, EDC, RTSM / IRT, Patient and Site Payments) will be rebranded and integrated into the established Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing innovative Clinical solutions for new customers as well.
The sale underlies Clario’s continuing commitment to focusing on clinical evidence generation backed by deep scientific expertise across its eCOA, Cardiac Safety, Respiratory and Medical Imaging business lines. Underpinning this commitment is Clario’s continued investments in new technologies (including AI/ML), endpoint data collection, and generating the richest and highest quality data for our customers.
Commenting on the sale, Chris Fikry, CEO of Clario, said, “Our clinical trial solutions business provides important support and services for our sponsors looking for an end-to-end solution for their clinical trial. Following a strategic review of the business, Clario determined the best path forward for this business was its sale to Sitero. Sitero is well-prepared to provide the strong strategic support the business needs to grow, and Clario looks forward to maintaining a partnership with the business going forward. ”
Clario was advised by Cain Brothers, a division of KeyBanc Capital Markets on the transaction.
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Snr. Director, Content and Communications
+44 7307 533 162